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INTRODUCTION
 Pneumocystis jiroveci pneumonia (PJP) is a respiratory disease 
that causes high morbidity and mortality among immunocom-
promised and HIV patients.1 In the United States, it remains the 
most common Acquired Immunodeficiency Syndrome (AIDS) 
defining illness. Though PJP can be life threatening, it is a treat-
able infection, so a rapid and accurate diagnosis is essential. Clin-
ically, these patients present with nonspecific respiratory symp-
toms and signs suggestive of pulmonary infection such as cough, 
fever, dyspnea, hypoxemia, and an abnormal chest x-ray. PJP 
prophylaxis is considered the standard of care for patients with 
CD4 counts of less than 200 cells/mm.2 PJP formerly occurred 
in 70 - 80% of HIV patients; however with prophylaxis and PJP 
treatment, the associated mortality has decreased to 20 - 40%.2-3
 Approximately 90% of PJP cases occurred in patients with 
CD4+ counts of less than 200 cells/mm.2 Other factors that are 
associated with increased risk for PJP include previous episodes 
of PJP, oral thrush, recurrent bacterial pneumonia, uninten-
tional weight loss, or higher plasma HIV RNA.4-5 Patients with 
a history of oropharyngeal candidiasis should receive chemo-
prophylaxis against PJP.3,4 Trimethoprim-sulfamethoxazole is 
the recommended prophylactic agent and one double-strength 
tablet (160 mg - 800 mg) daily is the preferred regimen.2 The 
diagnostic test of choice for PJP pneumonia is fiberoptic bron-
choscopy with bronchoalveolar lavage and identifying the or-
ganism either by direct visualization with stains or by poly-
merase chain reaction (PCR). Prognosis for the patient depends 
on underlying comorbidities and immunological status.6 
 Autoimmune hepatitis is a chronic disease that can occur 
in patients of all ages and all ethnicities.7 However, it is seen 
most commonly in females between 40 - 50 years old. A diagno-
sis of autoimmune hepatitis usually is made and characterized 
by clinical signs and symptoms, laboratory abnormalities, the 
presence of antibodies, and the concentration of serum globulin. 
Some of the most common symptoms include fatigue, icterus, 
abdominal discomfort, abdominal distension, dark urine, pale 
stools, and pruritus. Physical exam findings may include sple-
nomegaly, ascites, hepatomegaly and epigastric tenderness.8 
 Characteristic laboratory findings in patients with autoim-
mune hepatitis can include an increase in bilirubin and abnor-
mal liver enzyme levels.8 Patients with autoimmune hepatitis 
also may have circulating serum antibodies, which can include 
anti-nuclear antibodies (ANA) and anti-smooth-muscle anti-
body (ASMA). It is also possible to see other antibodies such 
as anti-liver/kidney microsomal antibodies (ALKM-1), anti-
liver cytosol antibodies (ALC-1), anti-double-stranded DNA 
(anti-dsDNA) and perinuclear anti-neutrophil cytoplasmic an-
tibodies (p-ANCA). On occasion, anti-mitochondrial antibod-
ies also may be found in association with all of the above.8-9 
The clinical manifestations range from asymptomatic to ful-
minant hepatic failure. Symptomatic patients with autoim-
mune hepatitis who are untreated have high mortality rates. 
The initial treatment for autoimmune hepatitis usually con-
sists of immunosuppression with steroids sometimes com-
bined with azathioprine.10 The 10-year survival for treated pa-
tients is 90% and includes patients with advanced cirrhosis.9 
 Two separate cases of documented autoimmune hepatitis are 
presented. Both patients were admitted to the hospital with se-
vere upper respiratory infectious symptoms and were diagnosed 
with pneumocystis jiroveci pneumonia. PJP is most common in 
patients with HIV/AIDS and patients diagnosed with cancer, 
but it is rare to find it in patients with autoimmune hepatitis.11 
 A literature search using PubMed revealed an article dis-
cussing PJP pneumonia and alcoholic liver disease.12 A litera-
ture search on PJP pneumonia patients with severe liver disease 
revealed one article about liver transplant patients who devel-
oped PJP, suggesting possible prophylaxis for such patients.13
CASE REPORT
 Table 1 discusses two patients with PJP pneumonia.
Table 1. Two cases of PJP pneumonia.  
Patient 1 Patient 2
Gender Female Male
Age 58 years old 31 years old
Admitted for: Hypoxemic respira-
tory failure, syncope, right 
pleural effusion, produc-
tive cough for 1 week
Recurrent jaundice, extreme 
fatigue, fever, dry cough, 
progressive abdominal 
distension, 20 lb weight 
gain since last discharge 3 
weeks prior
Past medical history: Breast cancer, hepatic 
encephalopathy, obesity, 
autoimmune hepatitis 
diagnosed 4 months prior
Alpha-1 antitrypsin defi-
ciency (diagnosed 2 weeks 
prior), esophageal varices, 
hypertension
Past surgical history: Multiple paracenteses and 
thoracenteses; bilateral 
breast reduction
Social history: Former smoker Former alcohol drinker; 
stopped 3 weeks prior
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Patient 1 Patient 2
Home medications Prednisone 20 mg daily for 
4 months
Azathioprine 100 mg daily 
for 4 months
Furosemide
Lactulose
Rifaximin
Prednisone for 16 days
Vital signs upon 
admission:
99.1F, 83/49 mmHg, 94 
bpm, 30 rpm on mechani-
cal ventilation
100.4F, 129/73 mmHg, 110 
bpm, 16 rpm on room air
Physical exam: Lungs: Diffuse crackles 
and rhonchi 
Abdomen: soft, mildly dis-
tended, decreased bowel 
sounds
Scleral icterus
Lungs: clear to ausculta-
tion bilaterally
Abdomen: soft, distended 
with ascites, diminished 
bowel sounds
Extremities: anasarca
Integument: jaundice
Neurological: mild 
asterixis
Pertinent laboratory 
work:
WBC: 15,840 µL
INR: 1.9
PTT: 32 seconds
AST 89 U/L
ALT: 43 U/L
Alkaline phosphatase: 
179 UL
Albumin: 2.7 g/dL
Total bilirubin: 7.1 mg/dL
WBC: 35,000 µL
INR: 3.2
PTT: 49 seconds
AST 192 U/L
ALT: 167 U/L
Alkaline phosphatase: 
320 UL
Albumin: 2.7 g/dL
Total bilirubin: 15.8 mg/dL
Antinuclear antibody titer: 
1:80
Anti-smooth muscle 
antibody: 30
Liver biopsy: PAS diastase-
resistant droplets
Alpha-1 antitrypsin phe-
notype: SZ
Model for End-Stage 
Liver Disease Score
26 30
Child-Pugh Classifica-
tion
Class C Class C
(1-3)-β-d-glucan (BG) 
assay:
Positive with > 500 pg/mL Positive with > 500 pg/mL
Pneumocystis by PCR: Positive x 2
376 DNA copies/mL and 
208 DNA copies/mL
Positive
> 1000 DN copies/mL
Procalcitonin on 
admission:
4.64 µg/L
Outcome: Expired due to multiorgan 
failure
Stabled, discharged home
 Patient 1 was transferred to our facility and required me-
chanical ventilator support for worsening hypoxemic respi-
ratory failure. She was started on broad spectrum antibiot-
ics and norepinephrine secondary to shock. She had a near 
complete opacification of the right lung from a pleural ef-
fusion (Figure 1). Fiberoptic bronchoscopy of the left upper 
and lower lobes showed purulent secretions in the left main 
stem and trachea. Thoracentesis showed straw-colored fluid.
 She remained thrombocytopenic and coagulopathic. Through-
out her hospitalization, she required transfusions of platelets 
and cryoprecipitate. Her (1-3)-β-d-glucan (BG) assay, performed
Figure 1. Chest radiograph demonstrated a right pleural effusion. 
on two different occasions, was positive with > 500 pg/mL. Her 
pneumocystis by PCR was positive on two different occasions. 
The first sample, obtained from a bronchoalveolar lavage in the 
left upper lobe, was positive with 376 DNA copies/mL. The sec-
ond sample was taken from the left lower lobe of the bronchoal-
veolar lavage and was positive for 208 DNA copies/mL. Organ-
isms were seen on cytology preparation. She also grew candida 
albicans in her lavage. All other cultures were negative. Despite 
all supportive efforts, she expired due to multi-organ failure.
 Patient 2 was admitted to the same hospital sixteen days pri-
or for worsening jaundice, symptoms of upper respiratory in-
fection, fevers, fatigue, nausea, vomiting, frequent nosebleeds, 
and intermittent joint pain primarily in his hands, knees, ankles, 
and shoulders. At that visit, he was placed on prednisone and 
evaluated for liver disease. His laboratory evaluation showed 
antinuclear antibody (ANA) positive at 1:80 with anti-smooth 
muscle antibody positive at 30. A transjugular liver biopsy was 
done and the pathology demonstrated PAS diastase-resistant 
droplets. He also had an alpha-1 antitrypsin phenotype of SZ.
 A chest radiograph (Figure 2) and a representative slice of 
computed tomography (CT) of his chest (Figure 3) demonstrated 
interval development of discrete pulmonary nodules in the mid 
lung zones bilaterally since his last chest x-ray from the previ-
ous admission. The pulmonary mass on the right measured 3.5 
cm and the pulmonary mass on the left measured 4.0 cm. A CT 
of his abdomen and pelvis demonstrated a liver with a slightly 
nodular contour, ascites, splenomegaly, and varices (Figure 4).
 He was started on broad spectrum antibiotics. A paracentesis 
drained 2.7 liters of ascites fluid. His (1-3)-β-d-glucan (BG) as-
say test was greater than 500 and he was started on micafungin 
while awaiting further results. Fiberoptic bronchoscopy with 
bronchoalveolar lavage was positive by PCR for PJP at greater 
than 1000 DNA copies/mL. His antibiotics were switched to 
trimethoprim-sulfamethoxazole to treat the infection. He began 
to improve with a decreasing WBC count. Once his liver failure 
stabilized and his infection was resolving, he was discharged 
with instructions to continue trimethoprim-sulfamethoxazole 
treatment for 21 days then remain on a prophylactic dose for PJP.
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Figure 2. Chest radiograph demonstrated bilateral lung masses. 
 
Figure 3. A representative slice of CT scan of the chest demonstrated 
pulmonary nodules. 
Figure 4. A representative slice of the CT scan of the abdomen demon-
strated a nodular contour of the liver.  
DISCUSSION
 It is rare to diagnose PJP in patients with liver disease, as it 
is most commonly found in patients with HIV or AIDS. While 
patient 2 had known alpha-1 antitrypsin deficiency, his biopsy 
and clinical situation were more consistent with acute autoim-
mune hepatitis as the main driver of his current liver disease 
and decompensation. The occurrence of pneumocystis jiroveci 
pneumonia in cases with autoimmune hepatitis is very rare. 
 The incidence of PJP can be due to the administration of cor-
ticosteroids causing immunosuppression or to liver cirrhosis. 
Typically, shorter periods of treatment with immunosuppres-
sive medications would not be associated with opportunistic 
infections. However, liver cirrhosis also is considered an immu-
nocompromised state that can lead to a variety of infections as 
well and infection is directly responsible for approximately 30% 
of deaths in cirrhotic patients.14-15 Cirrhosis will cause a system-
ic immune dysfunction which can decrease the ability to clear 
cytokines, bacteria and endotoxins from circulation. The liver 
contains reticuloendothelial cells which are central to clearing 
bacteria.14 Additionally, patients with cirrhosis have decreased 
neutrophil mobilization and phagocytic activity. The level 
at which this happens can vary with the severity of liver dis-
ease.14,16 Since PJP can be life-threatening, prompt diagnosis and 
treatment is imperative. It is felt that the “two hits” of liver fail-
ure with immunosuppression was sufficient to place these pa-
tients at risk for PJP infection with shorter periods of treatment 
with immunosuppression than is usually considered significant.
 The use of corticosteroids is a risk factor for PJP.17 In a large 
consecutive series of 116 patients without AIDS, patients with 
their first episode of PJP were analysed. Systemic corticoste-
roid therapy was administered to most of these patients the 
month before the onset of PJP. While it was not suggested 
that administration of corticosteroids is the only contributor 
to the development of PJP, PJP prophylaxis should be con-
sidered in patients where prolonged systemic corticosteroid 
therapy is prescribed.18 An anti-inflammatory effect usually is 
obtained by administering 0.1 - 0.3 mg/kg per day of predni-
sone. However, higher dosages are required (ranging from 1 
- 2 mg/kg/day) to produce faster immunosuppressive action.19 
 To treat autoimmune hepatitis, the standard therapy from 
clinical trials is prednisone or prednisolone at 30 - 60 mg/day 
alone or a lower steroid dose (20 - 30 mg/day) in combination 
with azathioprine (1 mg/kg/day).9 Both are equally effective 
in the management of the patients with severe autoimmune 
hepatitis. Corticosteroids act rapidly on the immune system by 
interfering with cytokine production and inhibition of T-lym-
phocyte activation. The steroid dose is tapered over six-weeks 
to three-months to a maintenance dose of 15 mg/day or less. 
Most patients will have normalized aminotransferases within 6 
- 12 weeks. Monitoring the response toward treatment includes 
serial aminotransferase and immunoglobulin measurement, 
and should be continued beyond normal laboratory results. A 
liver biopsy is recommended at the time of diagnosis because 
many patients have established cirrhosis at presentation.7
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 It may be beneficial for patients with autoimmune hepa-
titis who have contracted PJP to undergo prophylactic treat-
ment for PJP with trimethoprim-sulfamethoxazole (one 
double strength 160 mg - 800 mg tablet daily), which is the 
recommended first line treatment for PJP in HIV-infected pa-
tients.20 Once the prophylactic treatment is initiated, it is rec-
ommended to continue for life.2 HIV-infected patients with-
out PJP prophylaxis have a significantly higher mortality 
with the effect being most pronounced in those with the low-
est CD4 counts. There are no studies to prove that the effect 
is similar to those with autoimmune hepatitis.21 However, PJP 
unrelated to HIV can occur in immunosuppressed patients 
having malignancy or on immunosuppressive agents.22-23 
 Physicians should be aware that PJP is a possibility in pa-
tients who are receiving steroids or other immunosuppressive 
therapy, have a malignancy, or suffer from liver cirrhosis. The 
best way to decrease mortality in patients who have PJP but do 
not have HIV would be to identify them quickly and start pro-
phylactic PJP therapy.22,24,25 Prophylaxis for HIV patients is in-
dicated when there is a CD4 count of less than 200 cells/mm.2,21 
A study performed in the UK suggested multiple steps to en-
sure proper treatment for PJP, including enhanced surveillance 
to characterize any additional groups of patients who may 
be at risk, increasing basic knowledge on pneumocystis jiroveci 
epidemiology, and ensuring adherence to current guidelines.26
 One possibility for the increase in diagnosis of PJP is diag-
nostic bias, improved diagnostic methods, particularly the PCR 
method, which are more sensitive than previous methods.26-27 
There also has been an increase in number of renal transplants 
and hematological malignancies over the past decade; howev-
er, the increase for PJP was far greater than both of these factors 
combined. Thus the overall increase in PJP diagnosis cannot be 
explained solely on these factors.26 Another reason that can ex-
plain the increase in PJP pneumonia is that patients are not re-
ceiving appropriate prophylactic therapy, which can lead to an 
increase in transmission.26 Finally, another possibility could be 
that patients are living longer on immunosuppressive regimens, 
giving opportunistic organisms a longer period of time to infect. 
 For the two patients reported here, the process of their dis-
ease and the reason that they contracted with PJP are unknown. 
These patients most likely suffered from PJP with shorter cours-
es of immunosuppression than usually is described, because of 
the second hit of immunosuppression due to cirrhosis. Perhaps 
the cirrhosis is a larger contributor to immunosuppression than 
once believed. Thus, with people living longer with cirrhosis, 
considerations of prophylaxis against opportunists when ad-
ditional immunosuppressants are added may be warranted.
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